HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an ...

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [17] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [19] - Operating loss narrowed by 33% to $19.7 million in 2025 compared to $29.3 million in 2024 [22] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] - Operating cash usage reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024 [23] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [17] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [18] - Revenue from AlterG products and services was $12.9 million, an 18% decline from 2024, primarily due to lower international sales [18] Market Data and Key Metrics Changes - Reimbursement coverage for ReWalk expanded to include three largest Medicare Advantage insurers in the U.S., covering over 16 million lives [13] - International distribution efforts accelerated following the receipt of CE mark, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and expand strategic scope [4] - Focus on cash flow positive operations while investing in innovations that will define the future of the company [3][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses [15] - The company is committed to continuous innovation and leveraging advanced robotics and AI technologies [10] Other Important Information - The company plans to increase investment in R&D to advance new products to market, including a recently acquired powered upper body exoskeleton [21] - The company will not provide guidance at this time due to significant transformations and pending agreements [14] Q&A Session Summary Question: How does the Oramed POD technology align with the company's commercial infrastructure? - Management indicated that the integration of Oramed's technology will drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27][31] Question: What is the timeline for the upper extremity robotic assistance product? - Management expects the product to take 18-24 months to complete, with a low barrier to entry for regulatory approval [32][33] Question: How should investors view the company's diversification into biotech? - Management emphasized that a diversified portfolio in med tech and biotech is beneficial, providing resilience and multiple opportunities for product commercialization [42][43] Question: What drove the additional execution in revenue? - Management attributed the revenue performance to improved understanding of reimbursement pathways and better payer coverage, with expectations for continued growth [49][50]

Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. ...

Core Insights - Lifeward is positioned as a diversified biomedical innovation company with a clear path to profitability through its strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology [1][2][3] Financial Aspects - The partnership allows Lifeward access to up to $47 million in capital through various funding mechanisms, including equity and milestone-based funding [3][4] - Lifeward aims to drive profitability from its established medical technology product portfolio while investing in complementary technologies [4][8] Strategic Opportunities - The integration of the POD™ platform provides Lifeward exposure to a significant biotechnology market, particularly in oral delivery of biologic drugs, which could transform treatment for chronic diseases [5][6] - The POD™ technology has been evaluated in clinical programs for diabetes, a market exceeding $80 billion annually, indicating substantial growth potential [6][7] Operational Focus - Oramed will manage and fund the clinical development of the POD™ platform, allowing Lifeward to concentrate on its existing MedTech business while benefiting from the biotechnology platform's potential [7][8] - Lifeward's strategy includes building a diversified biomedical portfolio that balances immediate revenue generation with long-term innovation opportunities [13]

Core Insights - Lifeward is positioning itself as a MedTech platform with a clear path to profitability and long-term Biotech potential through a strategic partnership with Oramed Pharmaceuticals [1][2] Investment and Financial Structure - Lifeward will receive up to $47 million in strategic investment from Oramed and another investor, which includes equity, convertible notes, milestone-based funding, and warrant coverage [2][14] - The investment structure aims to support Lifeward's journey to profitability while allowing for selective investments in high-value innovations [2] Technology Acquisition - Lifeward is acquiring Oramed's Protein Oral Delivery (POD™) technology, which targets the $600+ billion injectable drugs market, including the potential for ORMD-0801 to become the first commercialized oral insulin [1][3] - The POD™ technology is designed to transform injectable biological therapies into oral medications, addressing a significant market opportunity in diabetes and other metabolic diseases [3][10] Clinical Development and Management - Oramed will manage and fund the clinical development of the POD™ technology, allowing Lifeward to focus on profitability and cash generation while retaining exposure to biotech opportunities [4][8] - The POD™ technology has shown promise in clinical trials, with the lead drug candidate ORMD-0801 achieving significant results in reducing HbA1c levels [12] Strategic Goals and Diversification - The partnership with Oramed marks the beginning of Lifeward's broader diversification strategy across medical technology and biotechnology [5] - Lifeward aims to achieve sustainable profitability from existing FDA-approved products while building a balanced biomedical portfolio that combines near-term revenue with long-term biotech innovation [6][7]

Core Viewpoint - Gilead Sciences, Inc. has entered into an agreement with the U.S. government aimed at reducing drug costs for Americans, emphasizing the company's commitment to innovation, affordability, and global health leadership [1][2]. Group 1: Agreement Details - The three-year agreement addresses President Trump's requests for a new pricing strategy that prioritizes American patients, ensuring the U.S. does not bear a disproportionate share of global healthcare costs [2][8]. - Key components of the agreement include discounts on certain existing medicines within the U.S. Medicaid program, pricing future medicines at parity with other developed nations, and launching a Direct-to-Patient Program for Gilead's Hepatitis C treatment, Epclusa [8]. Group 2: Financial Impact and Investments - Gilead anticipates that the financial impact of the agreement will be manageable starting in 2026 and beyond [3]. - The company plans to invest $32 billion in U.S.-based manufacturing, R&D, and infrastructure over the next five years, which is projected to generate $43 billion in national economic value and create over 3,000 direct and indirect jobs [5]. Group 3: Global Health Commitment - The agreement reinforces America's leadership in global health and biomedical innovation, building on Gilead's partnership with the U.S. Department of State to provide its HIV prevention medicine, lenacapavir, at no profit to up to two million individuals in severely affected countries over the next three years [4].